Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
NCT06793449

BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-08-03

80

Participants Needed

1

Research Sites

303 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective, non-inferiority study comparing VRD±D followed by BCMA CAR-T cell therapy versus VRD±D followed by autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients.

CONDITIONS

Official Title

BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Be informed and voluntarily sign the Informed Consent Form (ICF).
  • Age between 18 and 70 years (inclusive).
  • Have measurable disease with Serum M-protein 651 g/dL, or quantifiable IgA or IgD levels for IgA or IgD-type myeloma.
  • Urine M-protein 65200 mg/24 hours.
  • If serum and urine M-protein do not meet thresholds, have an abnormal free light chain (FLC) ratio (normal range: 0.26 to 1.65) and involved serum FLC 65100 mg/L.
  • Confirmed BCMA expression on multiple myeloma cells by flow cytometry or bone marrow immunohistochemistry.
  • Assessed by the investigator as transplant-eligible.
Not Eligible

You will not qualify if you...

  • Primary plasma cell leukemia.
  • Concurrent amyloidosis.
  • Involvement of the central nervous system (CNS).
  • Previous treatment with BCMA-targeted therapy or CAR-T cell therapy.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences

Tianjin, China

Actively Recruiting

Loading map...

Research Team

G

Gang An, PhD&MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here